PEX-168 improves insulin resistance, inflammatory response and adipokines in simple obese mice: a mechanistic exploration
Open accessPublished version of a preprint
The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.
Abstract
Background: Polyethylene glycol loxenatide (PEX-168) is a new antidiabetic drug; as such, there are not yet any reports on its weight loss effect. Therefore, this trial was designed to investigate the effect of PEX-168 on simple obese mice. Methods: Thirty healthy male C57BL/6 mice were randomly selected and divided into a control group (NC) and an obesity model group. The high-fat diet-induced simple obesity mice were divided into a model control group (HF) and three intervention groups. The intervention groups were injected with different doses of PEX-168 intraperitoneally once a week for 12 weeks (low (LD), medium (MD) and high (HD)). Fasting blood glucose (FBG), body weight and food intake were measured from 1 to 12 weeks after PEX-168 injection. The serum insulin (INS), C-reactive protein (CRP), chemerin and omentin levels were measured after 12 weeks. Results: Compared with the HF group, the low dose of PEX-168 reduced the body weight of the mice in a short period of time (8 weeks), and the mice in the MD and HD groups showed a significant decrease in body weight ( P < 0.05). The low dose of PEX-168 could effectively improve the blood glucose and homeostasis model assessment of insulin resistance (Homa-IR) of the mice (FBG P < 0.05 INS, Homa-IR P < 0.001), but there was no significant difference between different doses ( P > 0.05). CRP levels in the MD and HD groups were significantly improved ( P < 0.05). The levels of serum chemerin and omentin in the intervention groups were also significantly improved ( P < 0.01), but there was no significant difference between the different doses ( P > 0.05). Conclusions: PEX-168 significantly reduced the body weight of simple obese mice and improved the insulin resistance. PEX-168 may regulate the expression of chemerin and omentin through its hypoglycaemic effect, and the weight-reducing effect of PEX-168 is unlikely to be the reason for the changes in both.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Guo (120) et al. found that PEX-168 significantly reduced the body weight of simple obese mice. The weight loss of the low dose (0.03 mg/kg) group, medium dose (0.1 mg/kg) group, and high dose (0.33 mg/kg) group were about 2g, 4g, and 1g (8 weeks).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [120]
In the citing paper
“PEX-168 is a new agent of long-acting GLP-1R agonist, which is molecularly modified from EX via amino acid modification and PEGylation (119), the first GLP-1R agonist modified by PEG to achieve long-term pharmacological action (120, 121).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [120]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Journal of Environmental Research and Public Health
(2013) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph · Cited by 7,753
Arteriosclerosis, Thrombosis, and Vascular Biology
(2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0b013e31822a51e2 · Cited by 1,109
Vilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970
Omentin Plasma Levels and Gene Expression Are Decreased in Obesity
de Souza Batista, C. M., Yang, R.-Z., Lee, M.-J., Glynn, N. M., Yu, D.-Z., Pray, J., Ndubuizu, K., Patil, S., Schwartz, A., Kligman, M., et al. (2007) · Diabetes · doi:10.2337/db06-1506 · Cited by 757
Dysfunctional Adiposity and the Risk of Prediabetes and Type 2 Diabetes in Obese Adults
Neeland, I. J., Turer, A. T., Ayers, C. R., Powell-Wiley, T. M., Vega, G. L., Farzaneh-Far, R., Grundy, S. M., Khera, A., McGuire, D. K., & de Lemos, J. A. (2012) · JAMA · doi:10.1001/2012.jama.11132 · Cited by 648 · cited 1×
“Therefore, new treatment options are of great significance for overweight and obese patients without type 2 diabetes to better manage their weight, and prevent or improve insulin resistance and inflammation, thereby reducing the risk of diabetes and improving their quality of life [7].”
Backgroundvan Can, J., Sloth, B., Jensen, C. B., Flint, A., Blaak, E. E., & Saris, W. H. M. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.162 · Cited by 537
Chemerin: at the crossroads of inflammation and obesity
Ernst, M. C., & Sinal, C. J. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2010.08.001 · Cited by 425 · cited 4×
“However, clinical trials have confirmed the safety of PEX-168 in regulating blood glucose in T2DM patients, and the risk of hypoglycaemia is very low with monotherapy.”
BackgroundInfluentialNauck, M. A., Kemmeries, G., Holst, J. J., & Meier, J. J. (2011) · Diabetes · doi:10.2337/db10-0474 · Cited by 392 · cited 1×
“The delayed gastric emptying induced by GLP-1 is influenced by a rapid response at the level of vagal activation, and the delay in gastric emptying by GLP-1 is significantly attenuated after long-term administration of GLP1 analogues[23], which was also consistent with the changes in intake of the intervention groups…”
ResultMirza, S., Hossain, M., Mathews, C., Martinez, P., Pino, P., Gay, J. L., Rentfro, A., McCormick, J. B., & Fisher-Hoch, S. P. (2012) · Cytokine · doi:10.1016/j.cyto.2011.09.029 · Cited by 358
Kim, D. D., & Basu, A. (2016) · Value in Health · doi:10.1016/j.jval.2016.02.008 · Cited by 353 · cited 1×
“maintain, and effective noninvasive treatments are limited[5].”
Tan, B. K., Adya, R., Farhatullah, S., Lewandowski, K. C., O’Hare, P., Lehnert, H., & Randeva, H. S. (2008) · Diabetes · doi:10.2337/db07-0990 · Cited by 273
The Inflammasome in Atherosclerosis and Type 2 Diabetes
Masters, S. L., Latz, E., & O’Neill, L. A. J. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001902 · Cited by 169
Potts, J. E., Gray, L. J., Brady, E. M., Khunti, K., Davies, M. J., & Bodicoat, D. H. (2015) · PLOS ONE · doi:10.1371/journal.pone.0126769 · Cited by 163
Epidemiology of Obesity and Associated Comorbidities
Andolfi, C., & Fisichella, P. M. (2018) · Journal of Laparoendoscopic & Advanced Surgical Techniques · doi:10.1089/lap.2018.0380 · Cited by 162 · cited 1×
“cades, which has caused health challenges among the world population [1].”
BackgroundThe abnormal lipid profile in obesity and coronary heart disease (CHD) in Pakistani subjects
Shabana, S., Shahid, S. U., & Sarwar, S. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01248-0 · Cited by 130
Newer GLP-1 receptor agonists and obesity-diabetes
Brown, E. E., Cuthbertson, D. J., & Wilding, J. P. H. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.009 · Cited by 111 · cited 1×
“The most common adverse reaction of GLP-1 RA is gastrointestinal reactions, which gradually decrease with a longer dosing time and are significantly dose-dependent[22].”
BackgroundKlinger, S., Poussin, C., Debril, M.-B., Dolci, W., Halban, P. A., & Thorens, B. (2008) · Diabetes · doi:10.2337/db07-1414 · Cited by 86
Role of C-Reactive Protein in Cardiovascular Disease
Backes, J. M., Howard, P. A., & Moriarty, P. M. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1d203 · Cited by 83 · cited 1×
“It is a nonspecific acute phase reactant that has traditionally been used to detect acute injury, infection and inflammation[25].”
BackgroundRock, C. L., Flatt, S. W., Pakiz, B., Quintana, E. L., Heath, D. D., Rana, B. K., & Natarajan, L. (2016) · Metabolism · doi:10.1016/j.metabol.2016.07.008 · Cited by 76
Miao, Z., Alvarez, M., Ko, A., Bhagat, Y., Rahmani, E., Jew, B., Heinonen, S., Muñoz-Hernandez, L. L., Herrera-Hernandez, M., Aguilar-Salinas, C., et al. (2020) · PLOS Genetics · doi:10.1371/journal.pgen.1009018 · Cited by 70 · cited 1×
“Obesity is a significant determinant of insulin resistance, and adipose tissue plays a key role in insulin resistance [17]; insulin resistance is a common pathophysiological condition of obesity and diabetes [18].”
BackgroundSung, K., Lee, M. Y., Kim, Y.-H., Huh, J. H., Kim, J., Wild, S. H., & Byrne, C. D. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.05.042 · Cited by 66 · cited 1×
“Obesity, inflammation and insulin resistance are closely related; obese patients without dyslipidaemia, insulin resistance, inflammatory state, and impaired fasting blood sugar have a very low risk of developing diabetes [21].”
BackgroundGao, C., Rao, M., Huang, W. G., Qin, W., Yan, P., Long, Y., Guo, M., Xu, Y., & Xu, Y. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1127-z · Cited by 52
Khound, R., Taher, J., Baker, C., Adeli, K., & Su, Q. (2017) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.117.310251 · Cited by 51 · cited 1×
“In Khound’s animal study[24], it was shown that elevated GLP-1 prevented the overproduc-”
BackgroundTewksbury, C. M., Crowley, N. M., Parrott, J. M., Andromalos, L., Isom, K. A., Smith, E., & Allison, K. C. (2019) · Obesity Surgery · doi:10.1007/s11695-019-04041-w · Cited by 39
Gao, F., Lv, X., Mo, Z., Ma, J., Zhang, Q., Yang, G., Liu, W., Li, Q., Zhou, J., Bao, Y., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14163 · Cited by 37
Liang, Y., & Qi, Y. (2020) · Public Health · doi:10.1016/j.puhe.2020.05.013 · Cited by 36
Shuai, Y., Yang, G., Zhang, Q., Li, W., Luo, Y., Ma, J., Chen, D., Yang, J., Wang, X., Hu, J., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14198 · Cited by 35 · cited 3×
“However, clinical trials have confirmed the safety of PEX-168 in regulating blood glucose in T2DM patients, and the risk of hypoglycaemia is very low with monotherapy.”
BackgroundWang, S., & Peng, D. (2012) · Lipids in Health and Disease · doi:10.1186/1476-511x-11-131 · Cited by 33 · cited 1×
“Obesity is not only a risk factor of cardiovascular disease and type 2 diabetes mellitus [2], but also increases the financial burden of medical care”
BackgroundYan, P., Li, L., Yang, M., Liu, D., Liu, H., Boden, G. H., & Yang, G. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.02.030 · Cited by 33 · cited 2×
“expression of omentin-1 are negatively associated with obesity and insulin resistance [16].”
BackgroundTronieri, J. S., Wadden, T. A., Walsh, O. A., Berkowitz, R. I., Alamuddin, N., Gruber, K., Leonard, S., & Chao, A. M. (2019) · Metabolism · doi:10.1016/j.metabol.2019.03.005 · Cited by 29 · cited 1×
“Many studies have demonstrated that overweight or obese people with type 2 diabetes have a better tolerance to the GLP-1 receptor agonist liraglutide, which can reduce food intake without increasing energy consumption, to achieve a good weight loss goal [9, 10].”
BackgroundYang, J., Ao, N., Jian, D., Wang, X., & He, Y. (2014) · Endocrine · doi:10.1007/s12020-014-0480-y · Cited by 25 · cited 1×
“In Yang’s study[29], it was suggested that the GLP-1 analogue liraglutide could improve insulin resistance in high-fat diet-induced obese mice by im-”
BackgroundRowicka, G., Dyląg, H., Chełchowska, M., Weker, H., & Ambroszkiewicz, J. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17207575 · Cited by 23 · cited 1×
“The concentration of chemerin was associated with BMI, adipocyte volume and number, and in adult obese patients, body weight was significantly and positively correlated with circulating chemerin levels[27].”
BackgroundC‐Reactive Protein and the Metabolic Syndrome: Useful Addition to the Cardiovascular Risk Profile?
Szmitko, P. E., & Verma, S. (2006) · Journal of the CardioMetabolic Syndrome · doi:10.1111/j.0197-3118.2006.05340.x · Cited by 13
Cited by
GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., & Zhang, X.-F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1085799 · Cited by 248
Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential
AL-Noshokaty, T. M., Abdelhamid, R., Abdelmaksoud, N. M., Khaled, A., Hossam, M., Ahmed, R., Saber, T., Khaled, S., Elshaer, S. S., & Abulsoud, A. I. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.101895 · Cited by 30
“Guo [292] et al. found that PEX-168 significantly reduced basic obese mice ’ s weight.”
Progress in the contrary effects of glucagon-like peptide-1 and chemerin on obesity development
Zhang, Q., Ye, J., & Wang, X. (2023) · Experimental Biology and Medicine · doi:10.1177/15353702231214270 · Cited by 15
“4,5 Chemerin, an adipokine with inflammatory properties, highly expressed in adipose tissue and liver, can regulate adipogenesis and adipocyte metabolism and is noted to be an important factor involved in the inflammatory process cascade.”
BackgroundInfluentialOmentin-1 and diabetes: more evidence but far from enough
Xu, J., Li, M., Jiang, X., Wang, Y., Ma, H., Zhou, Y., Tian, M., & Liu, Y. (2023) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2023.2230380 · Cited by 7
“…t2DM patients (Yan et al. 2011). in obese mice, 12 weeks of polyethylene glycol loxenatide (PeX-168) treatment led to improved serum omentin levels (Guo et al. 2021). in addition, reduced oment-1 expression in adipose tissue and its concentration in circulation in rats owing to a high-fat diet…”
Self-citationXuefeng, R. E. N., Zhang, J., XIANG, H., Zhou, Q., Ge, S., & Huiling, X. U. E. (2024) · Chinese Journal of Analytical Chemistry · doi:10.1016/j.cjac.2024.100466 · Cited by 2
Metadata
- Authors
- Guo, Z., Wu, Y., Zhu, L., Wang, Y., Wang, D., & Sun, X.
- Affiliations
- Yangzhou University (CN)
- Northern Jiangsu People's Hospital (CN)
- Corresponding author
- Sun, Xiaofang
- Venue
- BMC Endocrine Disorders
- Published
- 2021-12
- Volume
- 21
- Issue
- 1
- Pages
- 245-245
- ISSN
- 1472-6823 (ISSN-L)
- PMC
- PMC8686575
- OpenAlex
- W4226060867
- Cited by
- 9
- References
- 34
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 2 · 2023: 3
- FWCI
- 0.90
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor, 19 d)
- Locations
- BMC Endocrine Disorders (publishedVersion, cc-by)
- Research Square (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Yangzhou University
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- GLP-1 receptor agonists, simple obesity, insulin resistance, weight loss, chemerin, omentin, adipokines, C-reactive protein, inflammation, high-fat diet-induced obesity, fasting blood glucose, HOMA-IR
- MeSH terms
- Animals, Disease Models, Animal, Hyperinsulinism, Hypoglycemic Agents, Inflammation, Insulin Resistance, Male, Mice, Inbred C57BL, Mice, Obese, Obesity, Peptides, Polyethylene Glycols, Mice, Adipokines, Diet, High-Fat
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
